Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has a collaboration agreement with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
08/23/19 1:03 AM EDT
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Aug 8 2019
Summary ToggleAdverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Aug 1 2019
Summary ToggleAdverum Biotechnologies Announces Board and Senior Management Changes
- Jul 25 2019
Summary ToggleAdverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
- Jul 15 2019
Summary ToggleAdverum Biotechnologies Appoints Senior Leaders
There are currently no events to display.